Diagnos Inc. announced that the Quebec government has given the green light to Diagnos' Artificial Intelligence (AI) technology to screen and assess Diabetic Retinopathy of patients served by the endocrinology departments of hospitals across the province. This positive milestone comes as the result of a collaboration project initiated in 2018, where Diagnos' technology was utilized to screen and classify the level severity of the Diabetic Retinopathy disease in patients of the endocrinology department from a major Quebec Hospital. The pilot phase of the project has been successfully concluded, resulting in the production of a final report by government officials.

This report has been disseminated to all hospitals in the province, highlighting the cost savings and other benefits of implementing DIAGNOS' technology. Specifically, the report found that using DIAGNOS' technology resulted in cost savings of $85 per patient, as well as additional savings from the optimization and reduction of time required from healthcare workers.